Cargando…

Assessing the impact of a restrictive opioid prescribing law in West Virginia

BACKGROUND: The Opioid Reduction Act (SB 273) took effect in West Virginia in June 2018. This legislation limited ongoing chronic opioid prescriptions to 30 days’ supply, and first-time opioid prescriptions to 7 days’ supply for surgeons and 3 days’ for emergency rooms and dentists. The purpose of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sedney, Cara L., Khodaverdi, Maryam, Pollini, Robin, Dekeseredy, Patricia, Wood, Nathan, Haggerty, Treah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852151/
https://www.ncbi.nlm.nih.gov/pubmed/33526045
http://dx.doi.org/10.1186/s13011-021-00349-y
_version_ 1783645763071377408
author Sedney, Cara L.
Khodaverdi, Maryam
Pollini, Robin
Dekeseredy, Patricia
Wood, Nathan
Haggerty, Treah
author_facet Sedney, Cara L.
Khodaverdi, Maryam
Pollini, Robin
Dekeseredy, Patricia
Wood, Nathan
Haggerty, Treah
author_sort Sedney, Cara L.
collection PubMed
description BACKGROUND: The Opioid Reduction Act (SB 273) took effect in West Virginia in June 2018. This legislation limited ongoing chronic opioid prescriptions to 30 days’ supply, and first-time opioid prescriptions to 7 days’ supply for surgeons and 3 days’ for emergency rooms and dentists. The purpose of this study was to determine the effect of this legislation on reducing opioid prescriptions in West Virginia, with the goal of informing future similar policy efforts. METHODS: Data were requested from the state Prescription Drug Monitoring Program (PDMP) including overall number of opioid prescriptions, number of first-time opioid prescriptions, average daily morphine milligram equivalents (MME) and prescription duration (expressed as “days’ supply”) given to adults during the 64 week time periods before and after legislation enactment. Statistical analysis was done utilizing an autoregressive integrated moving average (ARIMA) interrupted time series analysis to assess impact of both legislation announcement and enactment while controlling secular trends and considering autocorrelation trends. Benzodiazepine prescriptions were utilized as a control. RESULTS: Our analysis demonstrates a significant decrease in overall state opioid prescribing as well as a small change in average daily MME associated with the date of the legislation’s enactment when considering serial correlation in the time series and accounting for pre-intervention trends. There was no such association found with benzodiazepine prescriptions. CONCLUSION: Results of the current study suggest that SB 273 was associated with an average 22.1% decrease of overall opioid prescriptions and a small change in average daily MME relative to the date of legislative implementation in West Virginia. There was, however, no association of the legislation on first-time opioid prescriptions or days’ supply of opioid medication, and all variables were trending downward prior to implementation of SB 273. The control demonstrated no relationship to the law. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13011-021-00349-y.
format Online
Article
Text
id pubmed-7852151
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78521512021-02-03 Assessing the impact of a restrictive opioid prescribing law in West Virginia Sedney, Cara L. Khodaverdi, Maryam Pollini, Robin Dekeseredy, Patricia Wood, Nathan Haggerty, Treah Subst Abuse Treat Prev Policy Research BACKGROUND: The Opioid Reduction Act (SB 273) took effect in West Virginia in June 2018. This legislation limited ongoing chronic opioid prescriptions to 30 days’ supply, and first-time opioid prescriptions to 7 days’ supply for surgeons and 3 days’ for emergency rooms and dentists. The purpose of this study was to determine the effect of this legislation on reducing opioid prescriptions in West Virginia, with the goal of informing future similar policy efforts. METHODS: Data were requested from the state Prescription Drug Monitoring Program (PDMP) including overall number of opioid prescriptions, number of first-time opioid prescriptions, average daily morphine milligram equivalents (MME) and prescription duration (expressed as “days’ supply”) given to adults during the 64 week time periods before and after legislation enactment. Statistical analysis was done utilizing an autoregressive integrated moving average (ARIMA) interrupted time series analysis to assess impact of both legislation announcement and enactment while controlling secular trends and considering autocorrelation trends. Benzodiazepine prescriptions were utilized as a control. RESULTS: Our analysis demonstrates a significant decrease in overall state opioid prescribing as well as a small change in average daily MME associated with the date of the legislation’s enactment when considering serial correlation in the time series and accounting for pre-intervention trends. There was no such association found with benzodiazepine prescriptions. CONCLUSION: Results of the current study suggest that SB 273 was associated with an average 22.1% decrease of overall opioid prescriptions and a small change in average daily MME relative to the date of legislative implementation in West Virginia. There was, however, no association of the legislation on first-time opioid prescriptions or days’ supply of opioid medication, and all variables were trending downward prior to implementation of SB 273. The control demonstrated no relationship to the law. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13011-021-00349-y. BioMed Central 2021-02-01 /pmc/articles/PMC7852151/ /pubmed/33526045 http://dx.doi.org/10.1186/s13011-021-00349-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sedney, Cara L.
Khodaverdi, Maryam
Pollini, Robin
Dekeseredy, Patricia
Wood, Nathan
Haggerty, Treah
Assessing the impact of a restrictive opioid prescribing law in West Virginia
title Assessing the impact of a restrictive opioid prescribing law in West Virginia
title_full Assessing the impact of a restrictive opioid prescribing law in West Virginia
title_fullStr Assessing the impact of a restrictive opioid prescribing law in West Virginia
title_full_unstemmed Assessing the impact of a restrictive opioid prescribing law in West Virginia
title_short Assessing the impact of a restrictive opioid prescribing law in West Virginia
title_sort assessing the impact of a restrictive opioid prescribing law in west virginia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852151/
https://www.ncbi.nlm.nih.gov/pubmed/33526045
http://dx.doi.org/10.1186/s13011-021-00349-y
work_keys_str_mv AT sedneycaral assessingtheimpactofarestrictiveopioidprescribinglawinwestvirginia
AT khodaverdimaryam assessingtheimpactofarestrictiveopioidprescribinglawinwestvirginia
AT pollinirobin assessingtheimpactofarestrictiveopioidprescribinglawinwestvirginia
AT dekeseredypatricia assessingtheimpactofarestrictiveopioidprescribinglawinwestvirginia
AT woodnathan assessingtheimpactofarestrictiveopioidprescribinglawinwestvirginia
AT haggertytreah assessingtheimpactofarestrictiveopioidprescribinglawinwestvirginia